Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - codeine phosphate hemihydrate, quantity: 30 mg; paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; pregelatinised maize starch; maize starch; povidone; crospovidone; stearic acid; colloidal anhydrous silica - codalgin forte is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg; doxylamine succinate, quantity: 5 mg; paracetamol, quantity: 450 mg - tablet, uncoated - excipient ingredients: stearic acid; crospovidone; glyceryl monostearate; magnesium stearate; lactose monohydrate; povidone; pregelatinised maize starch - dolased forte is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

3m australia pty ltd - articaine hydrochloride, quantity: 40 mg/ml; adrenaline (epinephrine) hydrochloride, quantity: 12 microgram/ml (equivalent: adrenaline (epinephrine), qty 10 microgram/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide; sodium sulfite - ubistesin forte is used for local and regional anaesthesia (infiltration and nerve-block anaesthesia) in dentistry during minor and complicated procedures in adults, adolescents and children 4 years of age and older.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg; paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: povidone; pregelatinised maize starch; croscarmellose sodium; maize starch; potassium sorbate; microcrystalline cellulose; stearic acid; magnesium stearate; purified talc - comfarol forte is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg; paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: stearic acid; maize starch; pregelatinised maize starch; povidone; magnesium stearate; purified talc; croscarmellose sodium; potassium sorbate; microcrystalline cellulose - prodeine forte is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 30 mg - tablet, uncoated - excipient ingredients: potassium sorbate; maize starch; povidone; purified talc; stearic acid; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch - panadeine forte is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

biomed aust pty ltd - methadone hydrochloride, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: water for injections; colour - biodone forte is indicated for the detoxification and maintenance treatment of dependence on opioid drugs.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 1004.43 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 148.91 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; titanium dioxide; hypromellose; macrogol 6000; macrogol 4000 - augmentin duo forte is indicated for the short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology) *urinary tract infections (uncomplicated and complicated); *lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; *upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; *skin and skin structure infection appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin duo forte. however when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the product information, therapy may be instituted prior to obtaining the results of bacteriological and susceptibility studies. once the results are known, therapy should be adjusted should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo forte should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo forte.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg; paracetamol, quantity: 450 mg; doxylamine succinate, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; magnesium stearate; purified talc; stearic acid; povidone; pregelatinised maize starch; crospovidone - indications as at 9 june 2020: mersyndol forte is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Marekani - Kiingereza - NLM (National Library of Medicine)

comfort lab, lp - benzyl alcohol (unii: lkg8494wbh) (benzyl alcohol - unii:lkg8494wbh), lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - for temporary relief of pain. if symptoms persist more than seven days, discontinue use and consult physician. topical anesthetic lidocaine hydrochloride benzyl alcohol polysorbate 20 propylene glycol boswellia serrata resin oil ilex paraguariensis leaf magnesium sulfate, unspecified spearmint oil alcohol triethanolamine sulfate xanthan gum water phenoxyethanol arnica montana flower water dimethyl sulfone carbomer 980 ethoxydiglycol behenate